Security record · archived quarter
APLS
Apellis Pharmaceuticals, Inc. · Healthcare · Biotechnology
8Tracked holders
—Δ holders
21.17MShares held
$811.69MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 99 | +3 | 79.10M | $3.12B | +14 | −12 |
| Q4 2025 | 97 | +1 | 73.39M | $1.84B | +2 | — |
| Q3 2025 | 19 | +1 | 50.24M | $1.14B | +1 | −1 |
| Q2 2025 | 16 | +2 | 43.69M | $756.24M | +2 | — |
| Q1 2025 | 11 | -2 | 24.93M | $545.30M | +1 | −3 |
| Q4 2024 | 13 | +2 | 23.82M | $760.24M | +3 | −1 |
| Q3 2024 | 10 | +2 | 20.37M | $587.46M | +2 | — |
| Q2 2024 | 8 | — | 21.17M | $811.69M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 16.39M | — | $628.67M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 16.39M | — | $628.67M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 16.39M | — | $628.67M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 16.39M | — | $628.67M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 16.39M | — | $628.67M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 16.39M | — | $628.67M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 1.79M | — | $68.60M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.79M | — | $68.60M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 1.28M | — | $48.96M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 1.28M | — | $48.96M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 1.08M | — | $41.41M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 246.88K | — | $9.18M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 246.88K | — | $9.18M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 246.88K | — | $9.18M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 205.91K | — | $7.90M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 153.89K | — | $5.90M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 153.89K | — | $5.90M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 27.55K | — | $1.06M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 320 holders, 137.95M shares, $5.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API